NephrologyNow The Ultimate Guide to Kidney Disease Research

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

This RCT did not find that a rituximab-based regimen was superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis.

• 

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. See the associated editorial.

• 

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.

de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group).   Ann Intern Med.   2009 May 19;150(10):670-80

This randomized controlled trial compared pulse versus oral cyclophosphamide for induction in ANCA vasculitis. No difference in efficacy was detected between the two arms but pulse treatment resulted in a reduced cumulative cyclophosphamide dose and caused fewer cases of leukopenia.

• 

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?

Nachman PH.   Nat Rev Nephrol.   2009 May;5(5):254-6

• 

Review article: Progress of treatment in ANCA-associated vasculitis.

Jayne D.   Nephrology (Carlton).   2009 Feb;14(1):42-8

• 

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA, European Vasculitis Study Group (EUVAS).   Ann Rheum Dis.   2008 Jul;67(7):1004-10

• 

Treatment for renal vasculitis and Goodpasture’s disease in adults.

Walters G, Willis NS, Craig JC.   Cochrane Database Syst Rev.   2008 Jul 16;(3):CD003232

• 

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.

Hu W, Liu C, Xie H, Chen H, Liu Z, Li L.   Nephrol Dial Transplant.   2008 Apr;23(4):1307-12

• 

Challenges in the management of microscopic polyangiitis: past, present and future.

Jayne D.   Curr Opin Rheumatol.   2008 Jan;20(1):3-9

• 

Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.

Saadoun D, Delluc A, Piette JC, Cacoub P.   Curr Opin Rheumatol.   2008 Jan;20(1):23-8

• 

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D'Cruz D, Guillevin L, Harper L, Jayne D, Luqmani R, Mooney J, Scott D, BSR and BHPR Standards, Guidelines and Audit Working Group.   Rheumatology (Oxford).   2007 Oct;46(10):1615-6

• 

Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review.

Bosch X, Guilabert A, Espinosa G, Mirapeix E.   JAMA.   2007 Aug 8;298(6):655-69

• 

Arterial Microaneurysms in Polyarteritis Nodosa.

Das CJ, Pangtey GS.   N Engl J Med.   2006 Dec 14;355(24):2574

•